

Nov 13, 2024

Dear Potential RXXI Sponsor,

Greetings from the Co-Chairs of **Recovery of Biological Products XXI**. For four decades, this invitation-only, biannual, conference has been acknowledged as the leading international forum for the presentation and discussion of new insights and advances in the purification of biological products. We, as co-chairs, are already busy at work, committed to upholding the key hallmarks of this not-for-profit conference series: (i) a consistently high-quality scientific program, (ii) participation of the top experts and technical leaders within the biological products purification field whether working in academia or industry, and (iii) engaging events and activities that provide opportunities for networking, intellectual exchange and creativity. We are in the final stages of site selection, and are on track to choose a venue early 2025 for an early summer 2026 conference.

For the RXXI conference in 2026, we expect 260 attendees representing Industry, Academia and possibly Government agencies such as the FDA. We will not be hosting any health care practitioners (HCPs) as part of the conference, nor will we have vendor exhibits, booths or other promotional activities beyond display of sponsor logos. We are planning for an agenda that mirrors prior recovery conferences including: 2-3 poster sessions, 11 - 13 oral sessions, 2-4 keynote presentations, possibly 4 workshop sessions. The conference will encompass topics such as harvest technology, mechanistic and mixed models, cell and gene therapy development and manufacturing, chromatographic separations, advances in vaccine development, continuous unit operations, etc. Please see enclosed example from the most recent conference held June 2024 in Oregon, USA.

Tangible benefits of sponsorship: Presentation of novel technology developed at/with the sponsor company, networking with peers and industry leaders, recognition as industry leader in Recovery of Biological Products.

The total target sponsorship amount is \$700,000. Prior conferences typically have about 45-55 sponsors, each contributing between \$5000 and \$35000 per conference.

Sponsorships have been solicited from leading Biotechnology companies such as Abbvie, AGC Biologics, Solventum, Astellas, AstraZeneca, Bayer, Avitide, Biomarin, Bristol-Myers Squibb, Boehringer-Ingelheim, Amgen, Catalent, MilliporeSigma, Pall Life Sciences, Cytiva, Thermofisher, CSL, Eli Lilly, Merck, Pfizer, Biogen, Janssen/J&J, Just-Evotec, Lonza, Novo Nordisk, JSR Micro, Bio-Rad, Genentech/Roche, GSK, Gilead, Seattle Genetics, Sangamo, Novartis, Takeda, Regeneron, Sanofi, Samsung Biologics, Vertex, and more.

As we plan RXXI, we welcome your perspective on the scientific content of the conference. Please do not hesitate to contact any of us with your ideas so that we can shape the next success story in the Recovery Conference Series! Thank you for your consideration.

The RXXI Co-Chairs,

Todd Przybycien



(412) 400 2623
przybt3@rpi.edu

Sanchayita Ghose



(315) 708 2455
Sanchayita.Ghose@bms.com

Hanne Bak



(914) 826 5654
Hanne.Bak@regeneron.com